Ultragenyx shareholders approve amended incentive plan, elect directors, ratify auditor

Ultragenyx Pharmaceutical Inc.

Stockholders approved Second Amended and Restated 2023 Incentive Plan, authorizing up to 11.5M new shares plus forfeited shares from prior plans.
Class III directors Matthew K. Fust and Amrit Ray, M.D. elected to Board for term expiring 2028.
Advisory vote on executive compensation received 55.1M for (68%) vs 26.1M against.
Ernst & Young ratified as fiscal 2025 independent auditor with 84.3M votes for.
Broker non-votes of 5.3M shares on director election, incentive plan, and say-on-pay proposals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.